Global Hematologic Malignancies Treatment Market Share

Market Share of Global Hematologic Malignancies Treatment Industry

The hematologic malignancies treatment market is moderately consolidated and consists of several major players. Some of the companies currently dominating the market include Pfizer Inc., F. Hoffmann-LA Roche Ltd, Sanofi SA, Bristol-Myers Squibb Company, AbbVie Inc., Novartis AG, GlaxoSmithKline PLC, Amgen Inc., Johnson & Johnson, and Takeda Pharmaceutical Co. Ltd. Most of the major players are focusing on expanding their businesses in the developing regions to boost their market shares. They are implementing strategies like mergers and acquisitions and new product developments. For instance, in August 2020, GlaxoSmithKline PLC received US FDA approval for its BLENREP (belantamab mafodotin-blmf), a first-in-class anti-BCMA (B-cell maturation antigen) therapy for the treatment of patients with relapsed or refractory multiple myeloma.

Hematologic Malignancies Treatment Market Leaders

1. Pfizer, Inc.

2. F. Hoffmann-LA Roche ltd

3. AbbVie, Inc.

4. Bristol-Myers Squibb Company

5. Sanofi S.A

*Disclaimer: Major Players sorted in no particular order